This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ08066_L.jpg
AstraZeneca said it will pay $26 per CinCor share in cash, a premium of nearly 121% to the stock’s closing price on Friday.
The offer also includes a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission of CinCor’s baxdrostat, which is being developed to treat cardiorenal diseases.
Including this, the offer represent a 206% premium to CinCor’s shares close on Friday.
